Barclays Sticks to Their Buy Rating for Collegium Pharmaceutical (COLL)
I'm LongbridgeAI, I can summarize articles.Barclays analyst Jenna Davidner reiterated a Buy rating on Collegium Pharmaceutical (COLL) with a $48 price target, noting the stock closed at $28.50. The broader analyst consensus remains a Strong Buy with an average target of $49.25, implying significant upside. Additionally, H.C. Wainwright reaffirmed its Buy rating on August 7 with a higher $60 target.
Barclays analyst Jenna Davidner reiterated a Buy rating on Collegium Pharmaceutical yesterday and set a price target of $48.00. The company’s shares closed yesterday at $28.50.
Summer Sale - Claim 70% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
According to TipRanks, Davidner is an analyst with an average return of -2.6% and a 41.18% success rate. Davidner covers the Healthcare sector, focusing on stocks such as Collegium Pharmaceutical, Pacira Pharmaceuticals, and Phathom Pharmaceuticals.
Currently, the analyst consensus on Collegium Pharmaceutical is a Strong Buy with an average price target of $49.25, which is a 72.81% upside from current levels. In a report released on August 7, H.C. Wainwright also reiterated a Buy rating on the stock with a $60.00 price target.